Use of migalostat in reducing the risk of cerebrovascular event in patients with fabry disease
AssigneeAmicus Therapeutics, Inc.
InventorsNina Skuban, Hjalmar Lagast
Life of this patent
Estimating the term…
Abstract
Provided are methods for the treatment of Fabry disease in a patient and/or reducing the risk of reducing the risk of a cerebrovascular (CBV) event in a patient having Fabry disease. Certain methods relate to the treatment of ERT-experienced or ERT-nave Fabry patients. Certain methods comprise administering to the patient about 100 mg to about 150 mg free base equivalent of migalastat for reducing the risk of a CBV event.
Claims21
A method of reducing the risk of a cerebrovascular (CBV) event in a patient having Fabry disease, the method comprising administering to the patient a formulation comprising an effective amount of migalastat or salt thereof every other day for at least 2 years, wherein the effective amount is about 100 mg to about 150 mg free base equivalent (FBE).
21-41. (canceled)
Dependencies are inferred from the claim text.